{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:35:58Z","timestamp":1788863758399,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clml.2020.11.021","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:42:49Z","timestamp":1607042569000},"page":"e284-e289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-7680","authenticated-orcid":false,"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-4202","authenticated-orcid":false,"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Tanenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"DeVincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Grunman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-2574","authenticated-orcid":false,"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pecora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.11.021_bib2","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.11.021_bib3","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W, et al. An international, randomized, double blind trial comparing denosumab with zoledronic acid (ZA) for the treatment of bone disease in patients (pts) with newly diagnosed multiple myeloma. Paper presented at: 16th International Myeloma Workshop; 2017; New Dehli, India. Abstract 546. March 1-4, 2017.","DOI":"10.1016\/j.clml.2017.03.047"},{"key":"10.1016\/j.clml.2020.11.021_bib4","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.021_bib5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review","volume":"26","author":"Sparano","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.11.021_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/jco.2016.34.26_suppl.85","article-title":"Validation of the Living With Cancer (LWC) PRO tool for identifying patients (pts) with cancer appropriate for end-of-life care consultations","volume":"34","author":"Paramanathan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1634\/theoncologist.2018-0238","article-title":"A\u00a0patient-reported outcome instrument to assess symptom burden and predict survival in patients with advanced cancer: flipping the paradigm to improve timing of palliative and end-of-life discussions and reduce unwanted health care costs","volume":"24","author":"Goldberg","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.11.021_bib8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1089\/jpm.2015.0459","article-title":"A\u00a0patient-reported outcome instrument to facilitate timing of end-of-life discussions among patients with advanced cancers","volume":"19","author":"Goldberg","year":"2016","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.clml.2020.11.021_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non\u2013small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.11.021_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.11.021_bib11","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","article-title":"Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial","volume":"33","author":"Bakitas","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.11.021_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jamaoncol.2015.5252","article-title":"Emergency department\u2013initiated palliative care in advanced cancer: a randomized clinical trial","volume":"2","author":"Grudzen","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib14","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1200\/JCO.2014.58.7824","article-title":"Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the ENABLE III randomized controlled trial","volume":"33","author":"Dionne-Odom","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.2016.16786","article-title":"Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial","volume":"316","author":"El-Jawahri","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.11.021_bib16","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial","volume":"35","author":"El-Jawahri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.2016.70.5046","article-title":"Effects of early integrated palliative care in patients with lung and gi cancer: a randomized clinical trial","volume":"35","author":"Temel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2020.11.021_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/SPC.0000000000000386","article-title":"How should we assess patient-reported outcomes in the onco-hematology clinic?","volume":"12","author":"Cannella","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clml.2020.11.021_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","article-title":"Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","volume":"143","author":"Lee","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.021_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","article-title":"Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs MP: results from the VISTA trial","volume":"89","author":"Delforge","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.11.021_bib23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.11.021_bib24","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.11.021_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.11.021_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1049909116646337","article-title":"Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment","volume":"34","author":"Kiely","year":"2017","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.clml.2020.11.021_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2020.11.021_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00520-012-1548-y","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"Acaster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.11.021_bib30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","article-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences","volume":"72","author":"Gulbrandsen","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.11.021_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.11.021_bib32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.clml.2020.11.021_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-12-35","article-title":"Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma","volume":"12","author":"Proskorovsky","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2020.11.021_bib34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.11.021_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","article-title":"Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction","volume":"43","author":"Wagner","year":"2012","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.clml.2020.11.021_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-6-13","article-title":"Validation of the MD Anderson Symptom Inventory multiple myeloma module","volume":"6","author":"Jones","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.11.021_bib37","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s11136-017-1660-z","article-title":"Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods","volume":"26","author":"Ramsenthaler","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2020.11.021_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.soncn.2017.05.006","article-title":"Patient reported outcomes in optimizing myeloma patients\u2019 health-related quality of life","volume":"33","author":"King","year":"2017","journal-title":"Semin Oncol Nurs"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:16Z","timestamp":1730529376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020306637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2152265020306637"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}